Presence of EBV DNA in Cerebrospinal Fluid is Associated with Greater HIV RNA and Inflammation.
This study aimed to investigate whether cerebrospinal fluid (CSF) EBV or CMV DNA was associated with viral, inflammatory and neuronal damage biomarkers in people living with HIV (PLWH). Epstein-Barr virus (EBV) and Cytomegalovirus (CMV) can infect several cells, replicate in the central nervous system and affect blood-brain barrier (BBB) integrity. EBV, CMV DNA and HIV RNA were measured on CSF, through RT-PCR, from PLWHs undergoing lumbar punctures for clinical reasons (excluding oncho-haematological comorbidities). Immune-enzymatic assays evaluated BBB inflammation and damage. Patients were stratified according to plasma HIV RNA levels in viremic (≥50 copies/mL) and aviremic (<50 copies/mL). We included 297 participants. Among 167 viremic patients CSF EBV and CMV DNA were detectable in 42 (25.1%) and 10 (6.3%) participants; among 130 aviremic subjects CSF EBV and CMV DNA were detectable in 12 (9.2%) and 0 (0%) participants, respectively. In viremic group detectable CSF EBV DNA was associated with CSF pleocytosis (p < 0.001), higher CSF HIV RNA (p < 0.001) and neopterin levels (p = 0.002). In aviremic participants detectable EBV DNA was associated with pleocytosis (p = 0.056), higher neopterin (p = 0.027) and immune globulins (p = 0.016) in the CSF; CSF escape was more common in those with detectable EBV DNA (50% vs 21.2%, p = 0.036). EBV DNA was frequently detected in the CSF of viremic and fewer aviremic patients on antiretroviral treatment. In PLWH without clinical evidence of encephalitis CSF EBV DNA was associated with higher biomarkers levels of neuronal damage/inflammation. The role of EBV reactivation in HIV-associated CNS disorders warrants further studies.